Belsomra vs Dayvigo: Which Sleep Medicine Works Better for Women?

What Are Belsomra and Dayvigo, and How Do They Work?

Both drugs block orexin receptors in the brain. Orexin (also called hypocretin) is a neuropeptide that keeps you awake. By blocking the two orexin receptor subtypes, OX1R and OX2R, these medications quiet the wakefulness signal rather than sedating the entire brain the way benzodiazepines and Z-drugs do. That mechanism difference matters: the brain stays capable of rousing you in a genuine emergency, and the risk of the complex sleep behaviors seen with Z-drugs appears lower.

Suvorexant was the first DORA approved by the FDA, receiving approval in August 2014. Lemborexant followed in December 2019. Because they share a mechanism, the two are often compared, but the trials that established each drug were independent and used different primary endpoints and patient populations.

Why the Mechanism Matters Especially for Women

Women metabolize many sedative-hypnotics more slowly than men. The FDA's 2013 recommendation to halve the starting dose of zolpidem in women was the clearest public example of this sex difference. With the DORAs, the pharmacokinetic data are less dramatic, but the FDA labeling for both suvorexant and lemborexant notes that plasma exposure is modestly higher in women, which is part of why starting at the lower approved dose is the standard recommendation for female patients.

The Trial Evidence: What Does the Research Actually Show?

No single trial has placed suvorexant and lemborexant head-to-head in the same study. Comparing them requires cross-trial synthesis, which carries limitations you deserve to know about. Patient populations, primary endpoints, comparator arms, and trial durations differed. The numbers below are not interchangeable.

Suvorexant: The Herring et al. Lancet Neurology 2014 Data

The key registration trial for suvorexant was published in Lancet Neurology in 2014 (Herring et al.). This was a phase 3, double-blind, placebo-controlled trial across two studies (Study 1 and Study 2) enrolling roughly 1,400 adults with chronic insomnia disorder.

Key findings from the suvorexant 20 mg arm at month 1:

• Subjective total sleep time (sTST) improved by approximately 22 minutes over placebo.
• Subjective wake after sleep onset (sWASO) decreased by roughly 28 minutes versus placebo.
• Subjective sleep onset latency (sSOL) improved by about 8 minutes over placebo.

The trial also reported next-morning somnolence in 7 percent of patients on suvorexant 20 mg versus 3 percent on placebo, which is a clinically meaningful difference. The authors noted that the orexin-antagonist mechanism produced fewer complex sleep behaviors than historical Z-drug data, though direct comparison within this trial was not possible.

Women made up roughly half of the enrolled population. The trial did not stratify outcomes by menopausal status, which is a real evidence gap for perimenopausal and postmenopausal women reading this.

Lemborexant: The SUNRISE-1 Trial (JAMA Network Open 2019)

SUNRISE-1, published in JAMA Network Open in 2019, was a phase 3, double-blind, placebo- and active-controlled trial. The active comparator was zolpidem extended-release 6.25 mg, giving the trial a practical reference point that the suvorexant trials lacked.

Key findings for lemborexant 10 mg at the end of the first treatment month:

• Latency to persistent sleep (LPS) by polysomnography improved by 9.6 minutes over placebo.
• Wake after sleep onset (WASO) improved by 40.7 minutes over placebo.
• Lemborexant 10 mg outperformed zolpidem ER on WASO at both months 1 and 6.
• Next-morning driving simulation performance was better with lemborexant 5 mg than with zolpidem ER at all time points studied, and lemborexant 10 mg was comparable to zolpidem ER by month 3.

The trial enrolled adults aged 55 and older, a population that includes large numbers of postmenopausal women. This older-adult focus is one of lemborexant's relative advantages in the evidence base for women in menopause and beyond.

Cross-Trial Comparison: What You Can and Cannot Conclude

| Endpoint | Suvorexant 20 mg (Herring 2014) | Lemborexant 10 mg (SUNRISE-1 2019) | |---|---|---| | Sleep-onset improvement | ~8 min over placebo (subjective) | 9.6 min over placebo (PSG-objective) | | WASO improvement | ~28 min over placebo (subjective) | 40.7 min over placebo (PSG-objective) | | Comparator arm | Placebo only | Placebo + zolpidem ER | | Next-morning alert data | Somnolence rate reported | Driving simulation performed | | Older-adult specific data | Limited subgroup | Primary enrollment ≥55 years |

The different measurement tools (subjective questionnaires vs. Polysomnography) make direct numeric comparison unreliable. Polysomnography tends to yield more conservative WASO numbers than patient-reported data, so lemborexant's 40.7-minute PSG improvement is not simply "better" than suvorexant's 28-minute subjective improvement. They are measuring related but distinct things.

A practical framework for women choosing between these two drugs: if your primary complaint is difficulty staying asleep and you are postmenopausal or 55-plus, the SUNRISE-1 data in your age group give lemborexant a meaningful evidence advantage. If you have tried lemborexant and experienced next-morning grogginess at the 10 mg dose, suvorexant at 10 mg is a reasonable alternative with years of post-market data behind it.

Women-Specific Dosing and Pharmacokinetics

Suvorexant Dosing in Women

The FDA-approved starting dose for all adults, regardless of sex, is 10 mg taken no more than 30 minutes before bed, with at least 7 hours remaining before the planned wake time. The 20 mg dose is available if 10 mg is ineffective, but FDA labeling cautions that the exposure-response relationship shows higher plasma concentrations at 20 mg contribute to next-morning impairment. Women's modestly higher plasma exposure at equivalent doses means the 10 mg starting point is particularly important for female patients.

Suvorexant is a CYP3A4 substrate. If you are taking a moderate or strong CYP3A4 inhibitor (fluconazole, certain HIV medications), your suvorexant exposure rises significantly. Dose reduction or avoidance is warranted.

Lemborexant Dosing in Women

The FDA-approved starting dose is 5 mg. The 10 mg dose is available if 5 mg is insufficient. The FDA labeling for lemborexant notes that AUC was approximately 28 percent higher in women than in men at equivalent doses, reinforcing the 5 mg starting point for women. Lemborexant is also a CYP3A4 substrate, and the same inhibitor cautions apply.

How Hormonal Status Changes the Picture

Estrogen influences the metabolism of many CYP3A4 substrates. In perimenopause and postmenopause, falling estrogen levels alter hepatic enzyme activity in ways that can shift drug exposure. This has not been formally studied for either suvorexant or lemborexant in trials stratified by menopausal status, and that gap in the evidence deserves honest acknowledgment.

What is studied: postmenopausal women are over-represented in insomnia trial populations because insomnia prevalence rises sharply at menopause. Up to 61 percent of postmenopausal women report chronic insomnia symptoms, compared with roughly 30 to 40 percent of premenopausal women. The SUNRISE-1 enrollment of adults 55 and older likely captured a predominantly postmenopausal female cohort, though the trial did not publish sex-stratified or menopause-stratified efficacy data.

Sleep Across Reproductive Life Stages

Reproductive Years (Roughly Ages 18 to 40)

Insomnia in this group is often tied to the menstrual cycle. Progesterone's sedative properties peak in the luteal phase; falling progesterone before menstruation correlates with lighter, more fragmented sleep. Premenstrual sleep disruption affects an estimated 30 percent of women with PMS or PMDD. Neither suvorexant nor lemborexant has been studied specifically in cycle-related insomnia, and both require reliable contraception (see pregnancy section below) due to fetal safety concerns.

PCOS is relevant here. Women with PCOS have higher rates of sleep-disordered breathing and insomnia. Treating only the insomnia without evaluating for obstructive sleep apnea misses a key driver. Both DORAs are generally not recommended as monotherapy when obstructive sleep apnea is suspected or untreated, because orexin suppression can theoretically reduce the arousal response to apnea events.

Perimenopause (Roughly Ages 40 to 52, Highly Variable)

This is the life stage where the conversation about DORAs gets most clinically active. Hot flashes and night sweats fragment sleep directly. Adding a DORA on top of untreated vasomotor symptoms is treating a symptom rather than its cause. The Menopause Society (formerly NAMS) 2023 Position Statement recommends addressing vasomotor symptoms first, typically with hormone therapy where appropriate, before layering in sleep-specific pharmacotherapy. If insomnia persists after vasomotor symptoms are controlled, a DORA is a reasonable next step and is considered preferable to benzodiazepines or Z-drugs in this age group.

Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment across all life stages per AASM guidelines. A DORA should complement CBT-I, not replace it.

Postmenopause (After the Final Menstrual Period Plus 12 Months)

This is where lemborexant's SUNRISE-1 evidence is most directly applicable. The older-adult trial population aligns closely with postmenopausal women in their late 50s and 60s. The driving simulation data from SUNRISE-1 are particularly reassuring for women who drive early in the morning: lemborexant 5 mg showed no significant impairment over placebo on the morning after dosing.

Pregnancy and Lactation Safety

If you are pregnant, trying to conceive, or not using reliable contraception, both suvorexant and lemborexant require a direct conversation with your prescriber before you fill the prescription.

Suvorexant in Pregnancy

Suvorexant is classified under the FDA's revised labeling framework as lacking adequate human pregnancy data. Animal reproductive studies showed adverse effects including increased embryo-fetal deaths and decreased fetal body weight at exposures above the human therapeutic range. The FDA prescribing information advises that suvorexant should be used during pregnancy only if the potential benefit justifies the potential fetal risk. In practice, most clinicians avoid it entirely in pregnancy.

Lemborexant in Pregnancy

The situation for lemborexant is similar. Animal data showed reduced pup survival and delayed developmental milestones at doses relevant to human exposure. No controlled human pregnancy data exist. Avoid lemborexant during pregnancy unless there is no safer alternative and the clinical situation is severe.

Lactation

Neither drug has published human lactation pharmacokinetic data. Given the lipophilic nature of both compounds and their molecular weights, transfer into breast milk is possible. The LactMed database (NIH) does not currently have sufficient data to make a risk quantification for either agent. Both manufacturers recommend avoiding use while breastfeeding.

Contraception Requirement

Because both drugs are Schedule IV controlled substances with fetal risk signals and neither has a safe-in-pregnancy designation, women of reproductive potential should use reliable contraception while taking either medication. This is particularly relevant for perimenopausal women who may still be cycling irregularly and may assume they are no longer at risk of pregnancy before the 12-month menopause confirmation point.

Who This Is Right For, and Who Should Look Elsewhere

Consider a DORA (Either Suvorexant or Lemborexant) If You:

• Have chronic insomnia disorder (symptoms 3 or more nights per week for 3 or more months) not resolved by CBT-I alone.
• Are postmenopausal with persistent insomnia after vasomotor symptom treatment.
• Have a history of substance use disorder and want to avoid benzodiazepine or Z-drug exposure.
• Are concerned about complex sleep behaviors (sleepwalking, sleep-driving) previously seen with zolpidem or eszopiclone.
• Are 55 or older with a primary complaint of staying asleep rather than falling asleep.

A DORA May Not Be the Right Fit If You:

• Are pregnant or actively trying to conceive.
• Are breastfeeding an infant.
• Have untreated moderate-to-severe obstructive sleep apnea (the arousal-suppression mechanism is a concern).
• Are taking a strong CYP3A4 inhibitor (the dose interaction may make either drug unpredictable).
• Have narcolepsy (orexin deficiency is the disease mechanism; blocking orexin further is counterproductive).
• Are in your reproductive years with PCOS and have not yet had a sleep study to rule out OSA.

Side Effects: Where the Two Drugs Differ in Practice

Both drugs share the class-level side effects: somnolence, headache, and dizziness. The differences in side-effect profile are subtle but worth knowing.

Next-morning grogginess: The SUNRISE-1 driving data give lemborexant 5 mg a modest advantage here. At the 10 mg dose, driving impairment was detected at 9 hours post-dose but resolved by hour 11 to 12. Suvorexant's 20 mg dose carries a similar morning-after warning. At 10 mg suvorexant, next-morning impairment data are more favorable.

Sleep paralysis and hypnagogic hallucinations: These are DORA class effects tied to the REM-sleep boundary changes that orexin suppression can produce. Both drugs carry this warning. The incidence in trials was low (<2 percent) but real.

Drug discontinuation: Neither drug shows the rebound insomnia or withdrawal severity seen with benzodiazepines after short-term use. Neither has been rigorously studied beyond 12 months of continuous use.

Can You Switch From Belsomra to Dayvigo?

Yes, switching is possible, but it requires more than simply substituting one tablet for another.

The practical switching approach most prescribers use:

1. Stop suvorexant at the end of a prescription cycle rather than mid-supply.
2. Start lemborexant at 5 mg the following night, not at the dose equivalent of your suvorexant.
3. Wait at least two weeks at 5 mg before evaluating whether to increase to 10 mg.
4. Monitor for 7 to 10 days, because orexin receptor pharmacology is similar between the two drugs and overstacking the effect is unlikely, but individual responses vary.

There is no pharmacokinetic contraindication to switching directly, since neither drug has a long half-life that requires a washout (suvorexant half-life approximately 12 hours; lemborexant half-life approximately 17 to 19 hours). The longer half-life of lemborexant is one reason some patients report more consistent sleep maintenance with it but also more next-morning residual effect at the 10 mg dose.

Discuss the switch with your prescriber. Switching between two Schedule IV controlled substances requires a new prescription in most states.

The Evidence Gap Women Deserve to Know About

Women have been systematically under-represented in sleep pharmacology trials. Neither the Herring et al. Suvorexant trial nor SUNRISE-1 published sex-stratified or menopause-stratified primary efficacy data. The pharmacokinetic exposure differences between women and men are documented in labeling but were not the basis for dose-finding in the original trials.

What this means for you: the doses in both drug labels were derived primarily from mixed-sex or male-dominated phase 2 data, and the women-specific exposure finding arrived later. The clinical implication is that starting at the lowest approved dose is not just conservative advice, it reflects real uncertainty about whether standard doses are calibrated to female physiology.

Research published in the journal Sleep has shown that women with insomnia disorder are more likely than men to be prescribed benzodiazepine receptor agonists rather than receiving CBT-I first, a pattern that predates DORA availability and likely continues. The availability of DORAs with a less concerning dependency profile is a step forward, but the absence of women-only or menopause-specific trial arms remains an active evidence gap.

Frequently Asked Questions